Rx CJC-Ipa

Sources

CJC-1295 Ipamorelin: the full reference list.

Every quantitative claim on this site maps to one of these sources. PubMed and DOI links included.

About these CJC-1295 Ipamorelin references

The CJC-1295 Ipamorelin references below are the complete source list for this site. Each cited claim across the mechanism, pharmacokinetics, comparison, and safety pages carries a bracketed number that maps to an entry here. The list spans the foundational human pharmacokinetic and synergy studies, the ipamorelin selectivity and DAC-chemistry papers, the growth-hormone-secretagogue safety review, read-across evidence from the GHRH analogue tesamorelin, and the most recent ghrelin-agonist research. Where a paper is paywalled, the DOI and PubMed identifier are provided so the original can be located. The full citation list renders in the references section.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  8. Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-8. ↗
  9. Hoffman DM, et al. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab. 1996;81(3):1123-8. ↗
  10. Devesa J, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol. 2021;12:636403. ↗
  11. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of male hypogonadism. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. ↗
  12. Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019;11:350-354. ↗
  13. Worm DJ, et al. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. J Pept Sci. 2018;24:e3119. ↗
  14. Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur J Med Chem. 2018;157:1500-1511. ↗
  15. Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024;268:107550. ↗